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Obesity is associated with increased inflammation and insulin resistance. In conditions with
chronic immune activation, low plasma vitamin B6-levels are described, as well as an
increased kynurenine:tryptophan-ratio (KTR). We investigated circulating tryptophan,
kynurenine and its metabolites, neopterin, B-vitamins, CRP, and HbA1c in individuals with
obesity before and after bariatric surgery.
Methods
This longitudinal study included 37 patients with severe obesity, scheduled for bariatric surgery.
Blood samples were taken at inclusion and at three months and one year postoperatively.
Results
We observed significant positive correlations between HbA1c and both 3-hydroxy-kynure-
nine and 3-hydroxyanthranilic acid at inclusion. After surgery, fasting glucose, HbA1C and
triglycerides decreased, whereas HDL-cholesterol increased. Tryptophan, kynurenine and
its metabolites, except for anthranilic acid, decreased during weight loss. The KTR and CRP
decreased while vitamin B6 increased during the year following operation, indicating
reduced inflammation (all p<0.05).
Conclusions
In patients with obesity subjected to bariatric surgery, levels of 3-hydroxykynurenine and 3-
hydroxyanthranilic acid seemed to be positively correlated to impaired glucose tolerance.
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One year following surgery, plasma levels of the kynurenine metabolites were substantially
decreased, along with a metabolic improvement. The relation of circulating kynurenine path-
way metabolites with biomarkers of metabolic impairment in patients with obesity needs fur-
ther evaluation.
Introduction
Severe obesity is associated with highly elevated risk of adverse health outcomes [1] including
type 2 diabetes (T2D), hypertension, dyslipidaemia, and cardiovascular diseases, as well as pre-
mature death and several forms of cancers [2]. Weight loss reduces existing co-morbidities in
patients with obesity and may cause remission of T2D [3]. Compared to lifestyle intervention
and pharmacological treatment, bariatric surgery leads to greater weight loss and metabolic
improvement in patients with severe obesity [4].
Adipose tissue has important endocrine functions regulating energy homeostasis, insulin
sensitivity, lipid and carbohydrate metabolism [5, 6]. In obesity, an increased number of pro-
inflammatory immune response cells are found in adipose tissue. Consequently, increased lev-
els of pro-inflammatory cytokines are found [7–9]. Inflammation in adipose tissue seems to
promote and accentuate insulin resistance, an early feature in the progression from normogly-
cemia to overt T2D [10].
The essential amino acid tryptophan is obtained from the diet. Tryptophan is mainly meta-
bolised through the kynurenine pathway and is a source for NAD+, an essential cofactor in
energy metabolism. A smaller portion of tryptophan is used to synthesize the neurotransmit-
ters serotonin and melatonin (Fig 1)[11]. In the liver tryptophan is metabolized by the enzyme
tryptophan 2,3 dioxygenase (TDO), induced by stress and steroids. Plasma levels of kynure-
nine, however, might be more closely linked to the activity of the inflammation-induced
enzyme indoleamine 2,3-dioxygenase (IDO) [12]. IDO is ubiquitously expressed and induced
by inflammatory cytokines such as IFNγ [13]. The ratio between circulating kynurenine and
tryptophan (KTR) in plasma is thus often used as a measure of IFN-γ activation. Neopterin,
which is released in large quantities by activated macrophages, is another well-established
marker of IFN-γ activity [14, 15]. Kynurenine metabolites have distinct roles in immune-regu-
lation or can be neuroactive [16, 17]. Several key enzymes in the tryptophan-kynurenine meta-
bolic pathway require pyridoxal 5’-phosphate (PLP, vitamin B6) or flavin adenine dinocleotide
(FAD, vitamin B2) as cofactors (Fig 1). PLP is the most commonly used serum marker of vita-
min B6 status and reflects the body store of this vitamin [18]. In conditions associated with
chronic inflammation low plasma levels of PLP have been described [19].
Obesity leads to low-grade chronic inflammation and is associated with increased risk of
metabolic diseases. Inflammatory markers may be useful as a diagnostic tool to identify sub-
jects with obesity at high risk of developing metabolic diseases. In this study we present a tryp-
tophan-kynurenine metabolite profile in plasma samples of patients with morbid obesity at
baseline, 3 and 12 months after bariatric surgery.
Materials and methods
Participants
The study includes 37 subjects undergoing bariatric surgery, either laparoscopic sleeve gastrec-
tomy (LSG) or biliopancreatic diversion with duodenal switch (BPD-DS), at the Department
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of Surgery at Førde Hospital, Norway. A total of 40 subjects were recruited to the study, but
three patients withdraw from surgery. LSG was performed by resecting along a size 32 French
tube from the pylorus to the cardia creating a gastric volume of 100 ml or less. BPD-DS was
performed by creating a slightly greater gastric tube, excluding 60% of the small bowel and
making a common channel of 10% of the small bowel length. Further details on the surgical
procedures can be found in previous publications [20, 21]. Criteria to be scheduled for bariat-
ric surgery were age 18–60 years, BMI 40 kg/m2 or 35.0 kg/m2 if at least one obesity-
related comorbidity (such as T2D, hypertension or dyslipidaemia) was present. T2D was diag-
nosed if fasting plasma glucose was 7.0 mmol/L and/or plasma glucose measured 2 hours
after intake of 75g of glucose was 11.1 mmol/L. Eligiblity criteria also included no alcohol or
drug abuse and no major psychiatric disorder. Participants were recruited during the period
from September 2010 to May 2012. In general, patients who had T2D treated with insulin,
were using two or more antihypertensive drugs and/or received lipid-lowering treatment were
scheduled for BPD-DS. Inclusion and exclusion criteria for taking part in the study were iden-
























Fig 1. The kynurenine pathway of tryptophan metabolism. IDO, indoleamine 2,3-dioxygenase; TDO, tryptophan
2,3-dioxygenase; KAT, kynurenine aminotransaminase; KMO, kynurenine 3-monooxygenase; KYNU, kynureninase;
3OH-kynurenine, 3-hydroxy kynurenine; 3OH-anthranilic acid, 3-hydroxy anthranilic acid; B6, vitamin B6 (pyridoxal
5‘-phosphate); B2, vitamin B2 (flavin adenine dinucleotide).
https://doi.org/10.1371/journal.pone.0192169.g001
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Thus, any missing data is due to patients not being able to attend follow-up appointments for
personal reasons or random errors in the data collection. All patients were alive at the end of
the study.
Clinical examination and blood sampling were performed two days before surgery and
repeated after 3 and 12 months. Weight was measured to the nearest 0.1 kilograms on elec-
tronic scales with participants dressed in light clothing, and height in standing position with-
out shoes was measured to the nearest millimetre. Body mass index (BMI) was calculated as
weight divided by the square of body length (kg/m2). Percentage excess body mass index loss
(%EBMIL) from baseline to the one-year follow-up was calculated using the formula 100-
((Follow-up BMI-25/Beginning BMI-25)x100).
At inclusion 10 out of 37 patients used multivitamin supplements. Following surgery, all
patients were instructed to take one multivitamin supplement daily. The subset undergoing
BPD-DS were also instructed to take 30.000 IE of 25(OH)D and 2 gram calcium carbonate per
day. At 3 months after surgery 28 patients reported the use of multivitamin supplements, con-
taining a daily dose of 1.6–1.7 mg of vitamin B2 (riboflavin), 18–20 mg vitamin B3 (niacin),
and 1.2–2.0 mg vitamin B6 (pyridoxine), in addition to other vitamins and minerals. After 12
months 32 patients used supplements.
The study was approved by the Western Norway Regional Committee for Medical Research
Ethics (ref.nr. 2009/2174). All enrolled subjects provided informed written consent, and the
study was performed according to the principles of the Declaration of Helsinki.
Biochemical analyses
All blood samples were drawn after a fasting period of at least twelve hours. Glucose, HbA1c,
CRP, total cholesterol, HDL-cholesterol, and triglycerides were measured immediately at the
Laboratory of Clinical Chemistry at Førde Hospital, using the Architect system from Abbot
Diagnostics (North Chicago, Illinois, USA). Samples stored in the biobank were frozen within
60 minutes and kept at -20˚C for 1–2 days before being stored at −80˚C.
Plasma concentrations of tryptophan, kynurenine, kynurenic acid, anthranilic acid,
3-hydroxykynurenine, xanthurenic acid, 3-hydroxyanthranilic acid, quinolinic acid, neop-
terin, pyridoxal 5´-phosphate (PLP), riboflavin, nicotinamide N1-methylnicotinamide, and
creatinine were analysed by liquid chromatography/tandem mass spectrometry (LC-MS/MS)
[22] at Bevital A/S, Bergen, Norway (www.bevital.no) by laboratory personnel blinded to the
clinical characteristics and identity of the patients. Estimated glomerular filtration rate (eGFR)
was calculated according to the Modification of Diet in Renal Disease (MDRD) Study Group
formula [23].
Statistical analysis
Continuous variables are reported as median (25th-75th percentiles) and categorical variables
as numbers (percentages). Where distributional assumptions were violated, measures were
either log10 transformed (kynurenic acid, anthranilic acid, 3-hydroxykynurenic acid,
xanthurenic acid, 3-hydroxyanthranilic acid, quinolinic acid, pyridoxal 5‘-phosphate, ribofla-
vin and N1-methylnicotinamide) or ranked (CRP) before used in parametrical tests. To assess
changes in baseline characteristics between inclusion and one year after surgery Friedman´s
test was used. Changes over time between repeated end-point measures were assessed with a
random intercept mixed model, adjusted for operation method and multivitamin supplement
use. Correlations among continuous variables were assessed by Spearman rank correlation,
corrected for age, gender and eGFR, as well as operation method when analysing correlations
between changes over time. All tests were two-sided and p-values < 0.05 were considered to
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be statistically significant. Statistical analyses were performed using SPSS statistics 22 for Mac
(IBM Corporation, New York, NY, USA).
Results
Baseline characteristics
Median age (25th-75th percentile) of the 37 participants was 48 (42.5–53.5) years, 25 (68%) par-
ticipants were females, and median BMI (25th -75th percentile) was 43.8 (40.9–47.6) kg/m2. At
inclusion 38% had diabetes, of which one patient had type 1 diabetes mellitus, 17% hyperten-
sion and 12% hypercholesterolemia. LSG was performed on 25 patients (68%) whereas 12
underwent BPD-DS (Table 1). For two of the participants EDTA-plasma samples at baseline
were missing, though there were blood samples of these patients at three months and one year
after surgery.
Patients selected for BPD-DS were older than the LSG patients and more frequently used
anti-diabetic drugs. This subset also had higher levels of HbA1c, tryptophan and 3-hydroxyan-
thranilic acid. No other statistically significant differences in baseline characteristics according
to bariatric surgical procedures were observed (Table 2).
Correlations at baseline
Correlations of plasma kynurenines, related inflammation markers and B vitamins with fasting
glucose, HbA1c, TG:HDL-ratio at baseline, adjusted for age, gender and eGFR, are shown in
Fig 2. None of the kynurenines were correlated to fasting glucose, whereas neopterin was
strongly, positively correlated to both fasting glucose and HbA1c. Both 3-hydroxykynurenine
and 3-hydroxyanthranilic acid showed strong positive associations to HbA1c, whereas
Table 1. Baseline characteristics of the study population according to bariatric surgical procedures.
All patients LSG BPD-DS
(n = 37) (n = 25) (n = 12) p-value
Females (%) 25 (68%) 18 (72%) 7 (58%) 0.41
Age (years) 48.0 (42.5–53.5) 44.0 (39.5–51.5) 52.5 (48.3–58.5) 0.011
BMI (kg/m2) 43.8 (40.9–47.6) 45.4 (41.5–47.6) 41.9 (38.3–51.0) 0.98
Smoking (%) 14 (38%) 9 (36%) 5 (41%) 0.74
Fasting glucose (mmol/L) 5.80 (5.30–8.63) 5.50 (4.95–6.30) 8.40 (5.93–15.6) 0.066
HbA1C (%) 5.60 (5.50–6.90) 5.60 (5.30–6.10) 7.15 (5.68–10.4) 0.003
Cholesterol (mmol/L) 4.90 (4.00–5.55) 4.75 (3.93–5.83) 4.90 (4.20–5.25) 0.684
Triglycerides (mmol/L) 1.44 (1.25–1.77) 1.43 (1.24–1.65) 1.49 (1.22–2.21) 0.286
HDL-cholesterol (mmol/L) 1.06 (1.00–1.20) 1.10 (1.00–1.28) 1.00 (0.90–1.20) 0.101
Creatinine (umol/L) 68.6 (59.1–76.0) 68.8 (59.2–74.7) 64.1 (58.5–82.7) 0.506
eGFR (mL min-1per 1.73m2) 94.3 (80.1–106) 94.2 (80.8–106) 97.1 (73.0–108) 0.140
Diabetes 13 (38%) 6 (24%) 7 (67%) 0.041
Diabetes medication 10 (30%) 3 (12%) 7 (67%) 0.003
Hypertension 17 (46%) 11 (44%) 6 (50%) 0.73
Hypercholesterolemia 12 (32%) 6 (24%) 6 (50%) 0.11
Values are given as median (25th to 75th percentile), or numbers (percentages). LSG, laparoscopic sleeve gastrectomy; BPD-DS, biliopancreatic diversion with duodenal
switch; BMI, body-mass index; eGFR, estimated glomerular filtration rate; Diabetes medication, if patents used oral antidiabetic drugs or insulin; Hypertension, if using
one or more antihypertensive drugs; Hypercholesterolemia, using lipid lowering medication. p-values are based on Anova, adjusted for age, gender and BMI.
p-values are based on chi square test
p-values are based on students t-test
https://doi.org/10.1371/journal.pone.0192169.t001
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3-hydroxykynurenine was also correlated positively to the TG:HDL-ratio. PLP was negatively
correlated to glucose and HbA1c. At inclusion, BMI was positively correlated to CRP
(p< 0.05), but we did not find correlations to any of the other markers measured in the study.
Changes in clinical and metabolic baseline characteristics after bariatric
surgery
As expected, patients had significant weight loss after surgery. In the whole group %EBMIL
was 89%. Reduction of body weight was higher in the BPD-DS group (%EBMIL 109% (85.7–
114)) than in the LSG group (%EBMIL 84.7% (70.0–91.4), p<0.005). Fasting glucose (17%),
HbA1c (13%), and triglycerides (39%) decreased while HDL-cholesterol (23%) increased, indi-
cating a more favourable metabolic profile one year after surgery.
Before surgery 13 patients were diagnosed with diabetes, 10 of these used oral anti-diabetic
drugs or insulin. After surgery none of the patients with T2D used insulin and only one patient
used oral anti-diabetic medication (Table 3).
Kynurenine pathway metabolites and inflammatory markers after bariatric
surgery
Circulating levels of metabolites in the kynurenine pathway of tryptophan metabolism at base-
line, 3 and 12 months after surgery are given in Table 4. We observed decreased plasma levels
of tryptophan and all the kynurenine pathway metabolites, except for anthranilic acid. These
changes were generally apparent within the first three months after surgery. In contrast,
anthranilic acid was unchanged at three months, but significantly increased after one year.
The KTR and CRP decreased after surgery, while levels of neopterin were unchanged (Fig 3).
Table 2. Circulating levels of kynurenines, neopterin and B vitamins at inclusion of patients undergoing bariatric surgery.
All LSG BPD-DS
(n = 35) (n = 23) (n = 12) p-value
Tryptophan and kynurenines
Tryptophan (μmol/L) 65.0 (60.1–73.4) 64.4 (59.9–72.5) 71.6 (64.4–78.3) 0.029
Kynurenine (μmol L) 1.68 (1.38–1.91) 1.58 (1.35–1.95) 1.77 (1.52–1.88) 0.483
Kynurenic acid (nmol/L) 58.7 (49.3–71.0) 55.3 (47.5–67.0) 71.0 (53.6–78.7) 0.245
Anthranilic acid (nmol/L) 16.7 (13.5–20.0) 14.7 (13.3–17.9) 19.6 (16.7–25.4) 0.076
3-Hydroxykynurenine (nmol/L) 52.0 (40.5–61.1) 50.6 (40.0–57.3) 52.1 (40.5–62.7) 0.061
Xanthurenic acid (nmol/L) 13.3 (9.93–20.7) 12.3 (8.63–18.2) 14.6 (12.5–21.8) 0.329
3-Hydroxyanthranilic acid (nmol/L) 38.8 (29.6–50.3) 37.2 (27.7–46.0) 50.0 (36.2–66.6) 0.042
Quinolinic acid (nmol/L) 460 (368–578) 451 (371–508) 489 (335–640) 0.567
Inflammatory markers
KTR (nmol/μmol) 24.8 (21.7–28.9) 24.6 (21.6–30.0) 25.8 (21.7–28.9) 0.612
Neopterin (nmol/L) 16.6 (14.6–20.1) 16.6 (14.3–18.7) 19.6 (14.6–24.4) 0.681
CRP (mg/L) 6.00 (4.00–15.5) 6.00 (4.00–13.5) 6.00 (3.25–16.5) 0.971
B-vitamins
Pyridoxal 5’-phosphate (B6) (nmol/L) 29.9 (21.8–50.2) 37.8 (19.2–52.5) 27.8 (21.8–34.9) 0.073
Riboflavin (B2) (nmol/L) 20.5 (14.4–31.1) 21.7 (14.8–31.7) 20.5 (12.8–29.4) 0.257
Nicotinamide (B3) (nmol/L) 295 (211–368) 303 (221–368) 266 (180–382) 0.783
N1-methylnicotinamide (B3) (nmol/L) 152 (104–189) 157 (104–192) 150 (101–189) 0.751
Values are given as median (25th to 75th percentile). LSG, laparoscopic sleeve gastrectomy; BPD-DS, biliopancreatic diversion with duodenal switch. P-values are based
on Anova, adjusted for age, gender and BMI between the LSG and BPD-DS group.
https://doi.org/10.1371/journal.pone.0192169.t002
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CRP was significantly reduced already three months after surgery and continued decreasing
one year post-operatively, while the KTR was unchanged at three months but reduced after
one year. Analysing the LSG and BPD-DS groups separately showed the same results as in the
combined group regarding CRP, neopterin, and the B vitamins measured, as well as the kynur-
enine metabolites, except for anthranilic acid, which was increased in the BPD-DS group but
not significantly changed in the LSG group.
























Fig 2. Correlations of fasting glucose, HbA1c and the triglyceride:HDL ratio with tryoptophan, kynurenine and
the kynurenine metabolites, inflammatory markers, vitamin B6 and vitamin B3 at baseline. Regression coefficient
based on Spearman rank correlation test, corrected for age, gender and eGFR, are shown in the figure. Tg, triglyceride;
HDL, high density lipoprotein; Trp, tryptophan; Kyn, kynurenine; KA kynurenic acid; AA, anthranilic acid; HK,
3-hydroxy kynurenine; XA, xanthurenic acid; HAA, 3-hydroxy anthranilic acid; QA, quinolinic acid; KTR,
kynurenine:tryptophan ratio; PLP, pyridoxal 5‘-phosphate. p-value< 0.05; p-value< 0.005.
https://doi.org/10.1371/journal.pone.0192169.g002
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Levels of PLP were not significantly changed at three months after surgery, but an increase
was observed after one year. The vitamin B3 form nicotinamide as well as the catabolite N1-
methylnicotinamide decreased three month after surgery, though the latter increased between
three months and one year. Levels of N1-methylnicotinamide at one year post surgery did not
Table 3. Patient characteristics at inclusion and after bariatric surgery.
Inclusion 12 months after surgery
(n = 37) (n = 34) p-value
Gender (% females) 25 (68%)
Age (years) 47.1 (42.5–53.5)
Smoking (%) 14 (38%) 10 (29%) 0.56
BMI (kg/m2) 43.8 (40.9–47.6) 27.1 (24.5–30.6) < 0.001
Glucose (mmol/L) 5.80 (5.30–8.63) 4.80 (4.60–5.30) < 0.001
HbA1C (%) 5.60 (5.50–6.90) 4.90 (4.50–5.20) < 0.001
Cholesterol (mmol/L) 4.90 (4.00–5.55) 4.45 (3.78–5.52) 0.086
Triglycerides (mmol/L) 1.44 (1.25–1.77) 0.88 (0.70–1.07) < 0.001
HDL-cholesterol (mmol/L) 1.06 (1.00–1.20) 1.30 (1.08–1.50) 0.002
Creatinine (umol/L) 68.6 (59.1–76.0) 63.6 (56.1–69.8) 0.003
eGFR (mL min-1per 1.73m2) 94.3 (80.1–106) 107 (85.0–123) 0.003
Diabetes 13 (38%) 2 (5%) <0.001
Diabetes medication 10 (30%) 2 (5%) 0.002
Hypertension 17 (46%) 5 (14%) <0.001
Hypercholesterolemia 12 (32%) 2 (5%) 0.001
Values are given as median (25th to 75th percentile) or numbers (percentages). BMI, body-mass index; eGFR, estimated glomerular filtration rate; diabetes medication, if
patients used per oral antidiabetic drugs or insulin; hypertension, if patients used one or more antihypertensive drugs; hypercholesterolemia, using lipid lowering
medication. P-values are based on Friedman´s Two.
https://doi.org/10.1371/journal.pone.0192169.t003
Table 4. Circulating levels of tryptophan, kynurenines and B vitamins before and after bariatric surgery.
Time after surgery (months)
Inclusion 3 12
(n = 35) (n = 31) (n = 32) p-value
Tryptophan and kynurenines
Tryptophan (μmol/L) 65.0 (60.1-73-4) 48.5 (41.6–54.7) 51.9 (43.8–60.3) < 0.001
Kynurenine (μmol L) 1.68 (1.38–1.91) 1.22 (1.06–1.33) 1.23 (1.02–1.33) < 0.001
Kynurenic acid (nmol/L) 58.7 (49.3–71.0) 29.2 (23.5–33.6) 30.0 (22.6–42.6) < 0.001
Anthranilic acid (nmol/L) 16.7 (13.5–20.0) 16.0 (13.7–22.8) 18.6 (15.2–30.7) 0.001
3-Hydroxykynurenine (nmol/L) 52.0 (40.5–61.1) 30.7 (26.7–37.2) 30.7 (22.9–37.9) < 0.001
Xanthurenic acid (nmol/L) 13.3 (9.93–20.7) 3.35 (2.62–6.00) 5.09 (3.13–8.19) < 0.001
3-Hydroxyanthranilic acid (nmol/L) 38.8 (29.6–50.3) 15.3 (13.5–19.7) 18.4 (14.6–25.1) < 0.001
Quinolinic acid (nmol/L) 460 (368–578) 314 (265–368) 285 (248–356) <0.001
B-vitamins
Pyridoxal 5’-phosphate (B6) (nmol/L) 29.9 (21.8–50.2) 33.0 (15.8–56.1) 43.4 (31.3–70.3) 0.006
Riboflavin (B2) (nmol/L) 20.5 (14.4–31.1) 14.5 (8.84–25.7) 23.1 (16.6–26.5) 0.002
Nicotinamide (B3) (nmol/L) 295 (211–368) 207 (155–255) 219 (166–272) 0.002
N1-methylnicotinamide (B3) (nmol/L) 152 (104–189) 74.0 (49.7–104) 119 (81.1–219) <0.001
Values are given as median (25th to 75th percentile). P-values are based on mixed models, adjusted for type of surgery and vitamin B supplementation.
https://doi.org/10.1371/journal.pone.0192169.t004
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significantly different from inclusion. Similarly, riboflavin (vitamin B2) decreased at three
months, but levels one year after surgery were not significantly different from the levels at
inclusion. The PLP-dependent ratios between 3-hydroxykynurenine:xanturenic acid, 3-hydro-
xykynurenine:3-hydroxyanthranilic acid and 3-hydroxykynurenine:kynurenic acid were all
increased at three months after surgery, but decreased significantly after 12 months compared
to 3 months.
In order to examine whether baseline metabolite levels could predict surgical outcomes, we
analysed whether BMI, HbA1c, fasting glucose, and the TG:HDL-ratio after surgery were
related to plasma kynurenines, inflammatory markers and B vitamins at baseline. Changes in
BMI one year after surgery did not correlate with the metabolite levels at baseline, but we
observed a positive association with changes in tryptophan (p = 0.07) and kynurenine
(p = 0.014). Changes in HbA1c one year after surgery were positively correlated with baseline
levels of 3-hydroxyanthranilic acid (p = 0.041) and tryptophan (p = 0.027). In addition,
changes in 3-hydroxykynurenine one year after surgery were positively correlated to the
changes in both HbA1c (p = 0.029) and the TG:HDL-ratio (p = 0.024). The analyses were
adjusted for age, gender, eGFR, and operation method.
Discussion
In the present study we observed a positive correlation between HbA1c and both 3-hydroxyky-
nurenine and 3-hydroxyanthranilic acid at baseline. One year after bariatric surgery plasma
levels of most kynurenine pathway metabolites were substantially decreased. In accordance
with previous studies weight loss was accompanied by reduced CRP and KTR, as well as
increased vitamin B6-levels. The beneficial metabolic effects one year after bariatric surgery
also included decreased levels of HbA1c, triglycerides, and remission of T2D in a high propor-
tion of patients [3, 24–26].
The role of the kynurenine pathway in obesity and during weight loss has been ambiguous.
In accordance with our study, a recent report on patients undergoing either gastric banding or
Roux-en-Y gastric bypass showed a decrease in tryptophan and kynurenine metabolites one
year after surgery [27]. However, others have shown that in patients undergoing gastric band-
ing levels of KTR and neopterin were unchanged two years after surgery [24]. In addition to
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Fig 3. Inflammatory markers after bariatric surgery. Samples were measured at baseline, 3 months and after one year in 37 patients undergoing bariatric surgery. P
values for trend over time are estimated with a random intercept mixed model, adjusted for type of operation and vitamin B supplementation. Data are given as
median (25th to 27th percentile).
https://doi.org/10.1371/journal.pone.0192169.g003
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the difference in follow-up time, a possible explanation for these contrarieties may lie in the
different procedures of bariatric surgery performed. Gastric banding is shown to be a less
effective method on long-term outcomes compared to LGS or BPD-DS [28], which were
applied in the present study.
After LSG and BPD-DS, food intake is restricted due to reduction of the gastric volume. In
patients undergoing BPD-DS the uptake of nutrients is also reduced since a part of the small
bowel has been bypassed. In this study bariatric surgery was followed by a decrease in plasma
tryptophan, kynurenine and all the kynurenine metabolites, except for anthranilic acid. The
reduction was most prominent at three months after surgery, while levels seemed to be stable
between three months and one year after surgery. Since circulating levels of tryptophan and
kynurenines generally are positively related [29], the observed changes might be related to
restricted food intake and decreased absorption of nutrients like tryptophan, especially during
the first months after surgery. Both KTR and CRP decreased after weight loss, indicating
decreased inflammation. Changes in these inflammatory markers after surgery were more
prominent between three and twelve months than between baseline and three months.
IFN-γ stimulates the production of neopterin by macrophages and also increases the con-
version of tryptophan to kynurenine through increased activity of IDO. We observed a
decrease in KTR, though levels of neopterin did not change significantly after weight loss. This
might indicate that mechanisms beyond IFN-γ activity contribute to the regulation of trypto-
phan to kynurenine conversion in patients with obesity. The metabolism of tryptophan to
kynurenine is also catalyzed by TDO, which is induced by stress hormones, such as cortisol
[11]. Patients with severe obesity and metabolic impairment have increased levels of cortisol
[30]. Thus, a decrease in obesity-related cortisol and TDO activation might contribute to the
observed reduction in KTR after weight loss.
Low levels of PLP are linked to conditions associated with inflammation, such as CVD and
metabolic syndrome [31, 32], but the mechanisms by which PLP is decreased are not fully
understood. Increased inflammation seems to be associated with higher cellular uptake and
catabolism of vitamin B6 [33]. Enhanced demand of PLP as a cofactor might lead to functional
deficiency [34]. Additionally, stress might cause PLP deficiency by activation of the PLP phos-
phatase due to increased levels of cortisol [35]. Thus, an increase in vitamin B6 status after bar-
iatric surgery as seen in our study might reflect reduced inflammation. The increase was
higher between three months and one year after surgery than between baseline and three
months. The decrease in the ratios between 3-hydroxykynurenine:xanturenic acid, 3-hydroxy-
kynurenine:3-hydroxyanthranilic acid and 3-hydroxykynurenine:kynurenic acid between
three months and one year after surgery might be related to the increased PLP.
Circulating levels of the vitamin B3 complex nicotinamide and N1-methylnicotinamide
decreased during the first three months after surgery, despite supplementation of vitamin B3.
Vitamin B3 is obtained directly from the diet or synthesized from dietary tryptophan [36]. The
observed decrease in vitamin B3 is possibly caused by restricted food uptake after bariatric sur-
gery, as also reflected by lower levels of tryptophan.
At baseline the kynurenine metabolites 3-hydroxykynurenine and 3-hydroxyanthranilic
acid were positively correlated with HbA1c. Circulating concentrations of both these trypto-
phan metabolites decreased significantly after weight loss. In addition, changes in 3-hydroxy-
kynurenine one year after bariatric surgery were positively correlated to changes in HbA1c
and the TG:HDL-ratio. The formation of 3-hydroxykynurenine is dependent on the enzyme
kynurenine 3-monooxygenase (KMO), which converts kynurenine to 3-hydroxy-L-kynure-
nine. KMO is present in macrophages in adipose tissue and it has been shown that KMO activ-
ity is positively correlated to HbA1c levels [37]. Additionally, elevated circulating levels of
3-hydroxykynurenine were shown in diabetic individuals with retinopathy [38]. Patients who
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were operated using BPD-DS had higher incidence of T2D than the patients operated with
LGS and at baseline these patients also had higher levels of 3-hydroxyanthranilic acid.
3-Hydroxyanthranilic acid is a downstream metabolite of 3-hydroxykynurenine, dependent
on the enzyme kynureninase. Possibly, understanding the role of 3-hydroxykunurenine and
3-hydroxyanthranilic acid could help elucidate why some individuals with obesity have an
increased risk of developing metabolic impairment compared to metabolically healthy individ-
uals with obesity.
Anthranilic acid was the only kynurenine metabolite measured that increased after weight
loss. A different regulation of anthranilic acid compared to other kynurenines measured in
individuals with obesity has previously been described [29]. Conversion of kynurenine into
anthranilic acid is catalysed by the PLP-dependent enzyme kynureninase [11], and anthranilic
acid increases in response to pyridoxine supplementation [39]. The increase in circulating PLP
after weight loss might explain some of the observed increase in anthranilic acid. Possibly, also
a reduction in the KMO activity after weight loss may favour the formation of anthranilic acid
instead of 3-hydroxykynurenine. Further studies on the role of anthranilic acid in inflamma-
tory conditions are needed.
It should be noted that patients in this study received multi-vitamin supplements containing
vitamin B2, B3 and B6 after surgery. This makes it difficult to evaluate the effect of reduced
inflammation vs. supplements or impaired vitamin uptake on measured levels of vitamin B3 and
B6. Although, supplementation of pyridoxine does not normalize the circulating levels of inflam-
matory markers [40], vitamin intake was adjusted for in our analysis. Additionally, the major
changes in B-vitamin levels and reduction in inflammatory markers occurred between 3 months
and one year after surgery, which might indicate that the increase in B vitamins were not mainly
caused by increased intake through supplements, but rather the metabolic and inflammatory
changes occurring during weight loss. Two different types of bariatric surgery were used in this
study, LSG and BPD-DS. The type of bariatric surgery performed possibly plays a role regarding
weight loss, metabolic improvement and decreased inflammation. Due to the small sample size
the present study was not designed to evaluate differences in the surgical procedures.
Conclusion
In summary, strong correlations between HbA1c and the kynurenine metabolites 3-hydroxy-
kynurenine and 3-hydroxyanthranilic acid were observed in patients with obesity scheduled
for bariatric surgery. Following surgery, vitamin B6 levels increased whereas KTR and CRP
decreased, indicating down-regulated inflammation after profound weight loss. The role of
kynurenine metabolites in the pathophysiologic pathways leading to metabolic impairment in
individuals with obesity needs further evaluation.
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